P2‐054: Predicting the progression of Alzheimer's disease by plasma‐based biomarkers

Background: Alzheimer’s disease (AD) is the most common form of dementia, at present there remains a need for accurate biomarkers that can predict disease progression. In recent years markers of prediction, early diagnosis and progression have been identified in plasma by our group. We have therefore selected a multiplexing approach using the immunobased MILLIPLEX MAP assays to validate our previously discovered biomarkers with the aim to identify a combination of markers that can predict disease progression. Methods: 430 Alzheimer’s disease subjects, 395 cognitively normal and 173 mild cognitively impairment subjects were recruited from 2 large multi-centre cohorts. EDTA plasma was collected and evaluated for 45 analytes, using immuno-based MILLIPLEX MAP assays. Samples were randomized, blinded to the clinical information and measured in duplicate. Results: The intra-assay precision was calculated as the coefficient of variation (%) for each analyte and was